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o r i g i n a l a r t i c l e
Nosocomial Transmission of New Delhi Metallo-b-Lactamase-1-
Producing Klebsiella pneumoniae in Toronto, Canada
Christopher F. Lowe, MD;1 Julianne V. Kus, PhD;1 Natasha Salt, BASc;2 Sandra Callery, MHSc;2 Lisa Louie, ART;2
Mohammed A. Khan, PhD;1 Mary Vearncombe, MD;1,2 Andrew E. Simor, MD1,2
design. An analysis of a cluster of New Delhi metallo-b-lactamase-1-producing Klebsiella pneumoniae (NDM1-Kp) and a retrospective
case-cohort analysis of risk factors for acquisition in contacts of NDM1-Kp-positive patients.
setting. A 1,100-bed Canadian academic tertiary care center.
patients. Two index patients positive for NDM1-Kp as well as 45 contacts (roommates, ward mates, or environmental contacts) were
investigated.
methods. Retrospective chart reviews of all patients colonized or infected with NDM1-Kp as well as contacts of these patients were
performed in order to describe the epidemiology and impact of infection prevention and control measures. A case-cohort analysis was
conducted investigating 45 contacts of NDM1-Kp-positive patients to determine risk factors for acquisition of NDM1-Kp. Rectal swabs
were screened for NDM1-Kp using chromogenic agar. Presence of blaNDM-1 was confirmed by multiplex polymerase chain reaction. Clonality
was assessed with pulsed-field gel electrophoresis (PFGE) using restriction enzyme XbaI.
results. Two index cases carrying NDM1-Kp with different PFGE patterns were identified. Nosocomial transmission to 7 patients (4
roommates, 2 ward mates, and 1 environmental contact) was subsequently identified. Risk factors for acquisition of NDM1-Kp were a
history of prior receipt of certain antibiotics (fluoroquinolones [odds ratio (OR), 16.8 (95% confidence interval [CI], 1.30–58.8); P p
], trimethoprim-sulfamethoxazole [OR, 11.3 (95% CI, 1.84–70.0); ], and carbapenems [OR, 16.8 (95% CI, 1.79–157.3);.005 P p .01 P p
]) and duration of exposure to NDM1-Kp-positive roommates (26.5 vs 6.7 days; )..04 P ! .001
conclusion. Two distinct clones of NDM1-Kp were transmitted to 7 inpatient contacts over several months. Implementation of contact
precautions, screening of contacts for NDM1-Kp carriage, and attention to environmental disinfection contributed to the interruption of
subsequent spread of the organism. The appropriate duration and frequency of screening contacts of NDM1-Kp-positive patients require
further study.
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The spread of gram-negative bacteria possessing the New
Delhi metallo-b-lactamase-1 (NDM-1) enzyme poses an
emerging threat to public health. The NDM-1 enzyme hy-
drolyzes all b-lactams, including penicillins, cephalosporins,
and carbapenems, with the exception of aztreonam.1 Tige-
cycline and colistin are often the only remaining active an-
timicrobial agents, since blaNDM-1-encoding plasmids typically
possess multiple resistance determinants.2
Since its discovery in a strain of Klebsiella pneumoniae
isolated from a Swedish patient previously hospitalized in
India in 2008,3 NDM-1 has been identified in multiple genera
of gram-negative bacteria and has disseminated worldwide.4
In Canada, colonization or infection with NDM-1-producing
organisms has primarily been associated with importation
from medical tourism or hospitalization during travel to an
endemic area.5-8 Autochthonous acquisition of NDM-1-pro-
ducing Morganella morganii has been described in Ontario
previously, indicating the potential for local acquisition of
blaNDM-1 in Canada.
5
Infection control guidelines for the prevention of carba-
penem-resistant Enterobacteriaceae (CRE) have been devel-
oped by the Public Health Agency of Canada.9 Perhaps be-
cause of the currently low incidence of CRE in Canada,10
infection control strategies for CRE are variable, with insti-
tutions in various stages of adopting new guidelines.11 In
January 2011, our institution identified an NDM-1-produc-
ing K. pneumoniae (NDM1-Kp) from a patient who had re-
cently returned from India. We describe the subsequent clus-
ter of nosocomial transmissions, the infection control
interventions adopted to prevent transmission, and a case-
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cohort analysis of risk factors for nosocomial acquisition of
NDM1-Kp.
methods
Study Site
The study site was a 1,100-bed tertiary care teaching hospital
in Toronto, Ontario, Canada. Research ethics board approval
was obtained for this study.
Infection Control Practices
Before January 2011, patients infected or colonized with CRE
were placed on contact precautions until the patient was dis-
charged. Admission screening for CRE was not routinely per-
formed but was done for contacts of patients with a newly
identified CRE. Contacts of CRE-positive patients were
preemptively placed on contact precautions and required 3
negative rectal screens over 2 weeks before discontinuation
of precautions. Urine, open wounds, indwelling devices, exit
sites, and endotracheal tube specimens were also collected for
screening, if appropriate. Ward surveillance (screening) once
a week for 3 weeks of all patients on a unit was conducted
when a new index patient was identified. If the point prev-
alence surveys were negative, no further investigation was
conducted.
Microbiology
Clinical samples were processed using conventional microbi-
ology methods. Antimicrobial susceptibility testing was per-
formed utilizing the VITEK2 automated system (bioMérieux).
Colistin and tigecycline susceptibility testing was performed
using Etest (bioMérieux). Clinical isolates with an ertapenem
minimum inhibitory concentration of 1.0 mg/L or greater un-
derwent confirmatory testing by Etest12 and in-house poly-
merase chain reaction (PCR) for the presence of carbapene-
mases. The multiplex PCR targeted the carbapenemases
blaNDM-1 and blaKPC using primers NDM1-F (5
′ AAA GTC AGG
CTG TGT TGC G 3′), NDM1-R (5′ ATC TCG ACA TGC CGG
GTT TC 3′),3 KPC-F (5′ ATG TCA CTG TAT CGC CGT CT
3′), and KPC-R (5′ TTG TCA TCC TTG TTA GGC GC 3′).13
PCR for other b-lactamases included blaCTX-M, blaTEM, blaSHV,
blaOXA-1, and blaCMY-2.
6 The 2011 EUCAST Enterobacteriaceae
breakpoints were used for colistin,14 while tigecycline suscep-
tibility was based on the product monograph of tigecycline
approved by Health Canada (susceptible, ≤2 mg/L; interme-
diate, 4 mg/L; resistant, ≥8 mg/L).15
Before July 2011, rectal swabs to screen for asymptomatic
CRE colonization were planted on MacConkey agar with cef-
podoxime (2 mg/L; Oxoid); after this time, these specimens
were planted on Colorex CHROMagar KPC (Alere). Suspi-
cious colonies (growth on MacConkey cefpodoxime agar and
resistance to ertapenem or any growth on the CHROMagar
KPC) were confirmed by PCR assay for carbapenemase-
encoding genes.
For environmental samples, gauze moistened with sterile
saline was used to swab surfaces. The gauze was then enriched
in Letheen Broth (Difco-BBL) for 18–24 hours at 37C, after
which ∼50 mL was plated onto CRE screening media using
a swab.
Pulsed-Field Gel Electrophoresis (PFGE)
Genetic relatedness of NDM1-Kp was analyzed by PFGE us-
ing a CHEF-DR III System (Bio-Rad Laboratories), according
to the Centers for Disease Control and Prevention PulseNet
protocol with the restriction enzyme XbaI.16
Case-Cohort Analysis
The medical records of all patients with NDM1-Kp were re-
viewed. Inpatient contacts of these patients who subsequently
had at least 1 negative rectal screen culture for NDM-1-pro-
ducing organisms were identified, and their medical records
were also reviewed. Contacts were designated as roommates,
ward mates, or environmental contacts. For patients with mul-
tiple exposures, categorization was based on the patients’ high-
est level of exposure (roommate 1 environmental contact 1
ward mate). Roommates were defined as patients who shared
a room occupied by an NDM1-Kp case at the same time, while
ward mates were patients who did not share a room with an
NDM1-Kp case but were on the same ward as a case patient.
Environmental contact was defined as a patient who was ad-
mitted to a room directly following the discharge of an NDM1-
Kp-positive patient but did not share a room with an NDM1-
Kp-positive patient previously. Duration of exposure to
NDM1-Kp for contacts was calculated on the basis of the cu-
mulative number of days spent at each exposure level (room-
mate vs ward mate vs environmental contact). Clinical data
including date of admission, location of hospital stay, level of
NDM1-Kp exposure (roommate, ward mate, or environmental
contact), clinical diagnosis, course in hospital, past medical
history, medical interventions (eg, surgery, central line inser-
tions, tracheostomy, Foley catheters), antibiotic history (within
3 months from a positive culture, the first negative CRE screen
for contacts, or the earliest exposure date for contacts dis-
charged before being screened for CRE), and history of col-
onization or infection with other antibiotic-resistant organisms
(methicillin-resistant Staphylococcus aureus, vancomycin-resis-
tant enterococci, extended-spectrum b-lactamase-producing
Enterobacteriaceae, and Clostridium difficile) were recorded.
Median time to detection for contacts was calculated on the
basis of the date of the first probable exposure to an NDM1-
Kp-positive patient to the contact’s first positive NDM1-Kp
culture (from any site).
Statistics
For categorical variables in the case-cohort study, univariate
analysis with the Fisher exact test was utilized. Student t test
was used for continuous variables (SAS 9.2). Statistical sig-
nificance was defined as a P value less than .05.
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table 1. Clinical Review of Patients with a Positive New Delhi Metallo-b-Lactamase-1 (NDM-1)-Producing Klebsiella pneumoniae Culture
Presumed
contact
Exposure length,
days First positive isolate
Infection
(site)
Estimated
time to
detection,
daysa
Mode of
detection
Previous negative
CRE screens
(dates)
NDM1-
KpPatient R W E Isolate Date
A Index 1 ... ... ... Urine January 19 Yes (UTI) ... Clinical No 1
B A 0 1 0 Urine April 18 Yes (UTI) 90 Clinical No 1
C B 0 11 0 Blood July 2 Yes (blood) 111 Clinical No 1
D C 29 0 0 Rectal July 5 No 30 Point prevalence screen No 1
E D 31 20 0 Rectal August 25 Yes (blood) 55 Point prevalence screen Urine, rectal (July 8, 14) 1
F E 24 35 0 Urine August 21 No 24 Point prevalence screen Urine, rectal (July 25) 1
G Index 2 ... ... ... Wound September 14 No ... Clinical No 2
H G 22 8 0 Rectal October 3 No 53 Contact tracing screen Urine, rectal (September 22) 2
I F (room) 0 0 18 Urine February 2, 2012 No 20 Contact tracing screen Urine, rectal (January 18) 1
note. CRE, carbapenem-resistant Enterobacteriaceae; E, environmental contact; NDM1-Kp, NDM-1-producing Klebsiella pneumoniae; R, roommate; UTI, urinary
tract infection; W, ward mate.
a Based on first probable exposure.
results
NDM1-Kp Cluster
Between January 2011 and March 2012, 9 patients were iden-
tified with NDM1-Kp. PFGE revealed 2 distinct clones. The
index patient for clone 1 had previously received health care
in India and was admitted to our institution for 7 days. Urine
cultures yielded NDM1-Kp postdischarge; therefore, the pa-
tient was not in precautions during his admission. The index
case for clone 2 had no previous travel to the Indian sub-
continent and was identified only after being discharged from
our hospital to a rehabilitation facility. Table 1 summarizes
the exposure history and microbiological investigation for
NDM1-Kp-positive patients. Nine patients were colonized
with NDM1-Kp, of which 4 patients had clinical infections
(2 urinary tract infections and 2 bloodstream infections). All
isolates of both clones of NDM1-Kp were resistant to all b-
lactams, fluoroquinolones, aminoglycosides, and trimetho-
prim-sulfamethoxazole (TMP-SMX) but susceptible to colis-
tin. Clone 1 had intermediate susceptibility to tigecycline,
while clone 2 was susceptible. PCR for b-lactamase genes
identified blaNDM-1, blaCTX-M, blaCMY-2, and blaSHV in clone 1,
while clone 2 possessed blaNDM-1, blaCTX-M, blaOXA-1, and blaSHV.
Median time to detection of NDM1-Kp in contacts after their
first potential exposure was 53 days.
Environmental contact accounted for transmission to 1
patient. Patient I occupied the same room that had previously
been shared by patients E and F for 166 days. Environmental
sampling of this room during patients E and F’s stay included
bed rails, light switches, bedside tables, ventilators, cardiac
monitors, supply carts, intravenous poles, and handwashing
sinks/faucets. NDM1-Kp was recovered only from culture of
the handwashing sinks/faucets in the room and was positive
(2/6 samples) on repeat testing 4 and 5 months after the
initial positive result. Screening of the bathroom sink in the
room was negative (0/14), as were sinks on other units where
NDM1-Kp-positive patients occupied (0/12). Repeat testing
of other environmental surfaces was not conducted, since all
initial cultures were negative.
Case-Cohort Analysis
In total, 126 patients were identified as contacts of NDM-1-
positive patients, with 45 available for follow-up (25 room-
mates, 15 ward mates, and 5 environmental contacts). Of the
7 patients who subsequently acquired NDM1-Kp, 4 (57.1%)
were roommates, 2 (28.6%) were ward mates, and 1 (14.3%)
was an environmental contact. Univariate analysis of potential
risk factors for NDM1-Kp acquisition identified a history of
certain antibiotics (penicillins, fluoroquinolones, macrolides,
TMP-SMX, vancomycin, and carbapenems) and mean du-
ration of exposure to NDM1-Kp-positive roommates as sig-
nificant (Table 2). Duration of exposure to an NDM1-Kp-
colonized or -infected patient for roommate contacts was
significantly longer in those that acquired NDM1-Kp com-
pared with those that did not (26.5 vs 6.7 days; ). AP ! .001
multivariate analysis of potential risk factors for NDM1-Kp
acquisition was not done, since the number of cases was too
small.
Infection Control Interventions
Admission screening for CRE was extended to include pa-
tients with a receipt of health care in an endemic region.
Following identification of a patient with NDM1-Kp, screen-
ing of contacts was done on days 1, 7, 14, and 21. Ward
prevalence screens were done when a new case was identified.
Over the course of the investigation, 22 patients were
screened within 1 week after suspected exposure; 10 com-
pleted 3 weekly screens separated by 1 week, 5 completed 2
weekly screens, and 7 had 1 negative follow-up screen. A flag
in the electronic patient record allowed identification of con-
tacts, enabling contact precautions and screening to be ini-
tiated for those who were not screened if they were readmitted
or seen in clinic. Fifteen patients had a subsequent visit to
our hospital (inpatient or outpatient) a median of 165 days
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table 2. Univariate Analysis of Potential Risk Factors for New Delhi Metallo-b-Lactamase-
1-Producing Klebsiella pneumoniae (NDM1-Kp) Acquisition in Inpatient Contacts
Risk factor
NDM1-Kp
OR 95% CI P
Positive
( )N p 7
Negative
( )N p 38
Type of exposure to NDM1-Kp
Roommate 4 21 1.08 0.16–8.38 1
Ward mate 2 13 0.77 0.07–5.58 1
Environmental contact 1 4 1.42 0.02–18.0 1
Duration of exposure to NDM1-Kp
Roommate 26.5 6.7 ... 14.4–25.6a !.001
Ward mate 18.5 27.9 ... 82.0–63.1a .79
Environmental contact 9.5 8.0 ... 17.7–20.7a .85
Healthcare exposures in past year
Our hospital 4 17 1.65 0.24–12.7 .69
Canadian hospital 2 7 1.77 0.14–13.8 .61
Non-Canadian hospital 0 1  0.01– 1
Direct transfer from another hospital 1 5 1.07 0.02–12.5 1
Long-term care facility 1 1 6.17 0.07–496.6 .29
Rehabilitation center 1 1 6.17 0.07–496.6 .29
Past medical history
Recurrent urinary tract infections 1 1 6.17 0.07–496.6 .29
Diabetes mellitus 1 5 1.07 0.02–12.5 1
Hypertension 3 16 1.03 0.13–7.05 1
Chronic heart condition 2 17 0.49 0.04–3.55 .68
Chronic pulmonary condition 2 7 1.77 0.14–13.8 .61
Chronic renal failure 0 11  0.65– .17
Malignancy 3 16 1.03 0.13–7.05 1
Medical interventions
Surgery 4 33 0.20 0.03–1.87 .09
Central line 6 20 5.4 0.55–261.9 .21
Intubation 7 30  0.41– .32
Tracheostomy 5 16 3.44 0.47–39.4 .22
Nasogastric tube 5 21 2.02 0.28–23.4 .68
Gastric feeding tube 3 11 1.84 0.23–12.8 .66
Foley catheter 6 25 3.12 0.32–154.4 .41
History of an antibiotic-resistant organism
MRSA 1 0  0.29– .16
VRE 0 0 ... ... 1
ESBL 1 1 6.17 0.07–496.6 .29
Clostridium difficile 0 4  0.16– 1
Antibiotic historyb
Any antibiotic 7 31  0.34– .57
Penicillin 6 10 16.8 1.61–799.3 .005
Cephalosporin
First generation 3 10 2.10 0.26–14.7 .39
Second generation 0 1  0.01– 1
Third generation 4 19 1.33 0.19–10.3 1
b-lactam/b-lactamase inhibitor 5 17 3.09 0.43–35.4 .24
Carbapenem 3 3 8.75 1.30–58.8 .04
Fluoroquinolone 6 10 16.8 1.79–157.3 .005
Aminoglycoside 0 0 ... ... 1
Trimethoprim-sulfamethoxazole 4 4 11.3 1.84–70.0 .01
Azithromycin 4 2 24.0 3.04–189.4 .003
Vancomycin 4 7 5.9 1.07–32.5 .05
note. CI, confidence interval; ESBL, extended-spectrum b-lactamase-producing Enterobacteriaceae;
MRSA, methicillin-resistant Staphylococcus aureus; OR, odds ratio; VRE, vancomycin-resistant
enterococci.
a 95% CI of the difference of the means.
b Receipt of antibiotics within 3 months before a positive culture, the first negative carbapenem-resistant
Enterobacteriaceae (CRE) screen for contacts, or the earliest exposure date for contacts discharged before
being screened for CRE.
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(range, 27–299 days) after suspected exposure. The majority
(8 patients) had only 1 follow-up negative screen, while 6
patients had 2 negative screens and 1 patient completed 3
weekly screens. If a patient was transferred to a long-term
care home or a nursing home, the receiving institution was
advised of the patient’s status as a contact. Where possible,
CRE screening was then completed at the receiving facility
(1 patient).
Routine practices—including hand hygiene, compliance
with contact precautions, and cleaning/disinfection stan-
dards—were reinforced. Hydrogen peroxide–based disinfec-
tant was utilized for daily room cleaning/disinfection, with a
second daily cleaning/disinfection of high-touch surfaces.
Specialized equipment or equipment with materials not com-
patible with hydrogen peroxide were disinfected by steam
cleaning. With NDM1-Kp identified in the handwashing sink
of a patient room, further investigation identified healthcare
workers using this sink to dispose of bath water and other
liquids. This practice was stopped, and the sink was subse-
quently disinfected with hydrogen peroxide at sporocidal con-
centrations. However, because the sink cultures continued to
grow NDM1-Kp, the sink and sink traps were replaced.
discussion
The cluster of NDM1-Kp cases in our institution was the
result of transmission of 2 distinct clones. Autochthonous
acquisition of NDM-1-producing organisms has been de-
scribed in nonendemic countries, including Canada.5,17 Its
identification in our center suggests a potentially higher bur-
den of blaNDM-1 in Ontario than previously appreciated, since
1 index case had no travel history to an endemic area. Active
surveillance is now recommended by local provincial guide-
lines that recommend admission screening of any patient with
a history of receipt of healthcare in an endemic region.18
However, these recommendations may change over time as
additional risk factors for CRE are identified.
Active surveillance of epidemiologic contacts is recom-
mended after the identification of CRE by screening for
asymptomatically colonized patients.9,19 However, the optimal
frequency and timing of screening of contacts is unknown.
Although there was a long duration between acquisition and
detection of NDM1-Kp in our study, this may be an over-
estimation, since routine screening was not conducted to de-
termine the earliest date that NDM1-Kp could be clinically
detected. In our experience, a single rectal swab for contacts
was inadequate, since 4 patients (Table 1) were negative on
initial screening but developed NDM1-Kp infection or col-
onization on subsequent screens without ongoing exposure
to NDM1-Kp-positive patients. This may be due to a low
burden of colonizing organism at the time of acquisition, to
inadequately collected specimens, or to use of an imperfect
screening test. Currently, there is no gold standard protocol
for CRE rectal screening swabs.20,21 With uncertainty regard-
ing the most sensitive media for the detection of CRE, initial
false-negative results may have occurred. Chromogenic media
designed for CRE appear to be able to detect CRE with high
minimum inhibitory concentrations but may be less sensitive
for low-level carbapenem resistance.21 Further study of
screening media, both chromogenic and nonchromogenic, is
required to determine the optimal approach for routine lab-
oratory detection of CRE in the absence of molecular detec-
tion assays.21,22
The role of the environment in transmission of CRE is
uncertain, but transmission of Klebsiella spp. and Pseudo-
monas aeruginosa through environmental reservoirs has been
described.23-25 Patient I acquired NDM1-Kp colonization after
occupying the room of a previously positive patient, with no
other NDM1-Kp-positive patient on the ward, suggesting an
environmental source for transmission. This highlights the
importance of maintaining meticulous cleaning and disin-
fection standards. Practices such as disposing fluids in hand-
washing sinks may potentially result in contamination of
these surfaces and should be discouraged; biofilm production
makes eradication of gram-negative organisms from sinks
extremely difficult.24,25
Analysis of risk factors for the acquisition of NDM1-Kp
in contacts identified a history of recent exposure to certain
antibiotics and duration of roommate exposure to be signif-
icant. Because the mode of transmission for Enterobacteria-
ceae is primarily through direct contact, patients with close
and prolonged exposure would be expected to be at higher
risk. Nosocomial clusters of NDM-producing Escherichia coli
and K. pneumoniae have been identified in nonendemic coun-
tries,26,27 including 1 report of transmission between 2 room-
mates in France.27 Although roommates represented the high-
est risk in our study, transmission also occurred in ward mates
and environmental contacts presumably via the hands of tran-
siently colonized healthcare workers. We did not attempt to
detect staff carriage of NDM1-Kp in this investigation.
A limitation of this study was the small sample size. The
majority of NDM1-Kp contacts were discharged from the
hospital before screening swabs could be taken, affecting the
interpretation of potential risk factors for acquiring NDM1-
Kp. This reflects the practical limitations involved in acutely
managing a cluster of transmissions. The results, though, re-
flect previous experience with nosocomial transmission of
CRE in nonendemic countries.27 In addition, there is limited
experience with the microbiologic workup of CRE environ-
mental screens, and as discussed previously, the gold standard
for CRE screening media has yet to be defined. As institutions
acquire more experience with NDM-1-producing bacteria,
standardization of practice will develop for the infection con-
trol of these organisms.
Although the isolation of NDM-1-producing organisms is
currently a rare occurrence in Canadian healthcare settings,
this cluster indicates that the prevalence of these organisms
is increasing even in nonendemic regions and that prompt
initiation of infection prevention and control practices is es-
sential to prevent transmission. Contact precautions for
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NDM1-Kp-positive patients are necessary for the duration of
admission, since carriage of NDM-1-producing organisms
can persist.28 Further investigation is required to determine
the optimal frequency and timing of screening of in-hospital
contacts of patients with NDM-1-producing organisms in
order to reduce the risk of nosocomial transmission. With
the implementation of several interventions—including the
use of contact precautions for NDM1-Kp-positive patients,
screening of inpatient contacts, flagging contacts for appro-
priate precautions on readmission, and careful environmental
cleaning—no further transmission of NDM1-Kp has been
identified in our institution since February 2012.
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